

REMARKS

Claims 1, 3, 6, 8-11, 17, 50, and 52-66 were pending and under consideration. In the present paper, claims 1, 50, 52, and 53 are amended and new claim 67 is presented for consideration. Thus, following entry of the present amendment, claims 1, 3, 6, 8-11, 17, 50, and 52-67 will be pending and under consideration.

Applicants acknowledge the PTO's indication of allowable subject matter in claims 52 and 53 and kindly thank the PTO for the same.

In addition, Applicants kindly thank the Examiner for the courtesy extended in an interview August 2, 2007, with Applicants' representatives Frances Putkey, Nikolaos C. George, and David C. Pauling. In the interview, each of the outstanding objections and rejections was discussed and Applicants' arguments as discussed below were presented to the Examiner. No agreement was reached regarding the patentability of the claims.

I. The Amendments to the Claims

The present paper presents an amendment to claims 1, 50, 52, and 53. The amendments to the claims are fully supported by the application as filed and therefore present no new matter. In particular, the amendment to claim 1 is supported throughout the application as filed and specifically, for example, by the specification at page 11, lines 9-15, at page p, line 6 to page 10, line 17, at page 16, line 19 to page 17, line 10, and at pages 121-122, Table 4. The amendments to claims 50, 52, and 53 merely cancel non-elected subject matter and place claim 50 in independent form by incorporating the limitations of claim 1 and therefore find support, for example, in the originally filed versions of these claims and the portions of the application cited as exemplary support for the amendment to claim 1. As the amendments to the claims are fully supported by the application as filed, no new matter is presented by the amendments.

The present paper further presents new claim 67. Claim 67 is fully supported by the application as filed and therefore presents no new matter. Specific support for new claim 67 may be found, for example, in the specification at page 35, lines 3-5, page 37, lines 21-22, page 40, lines 6-13, page 48, lines 1-5 and lines 8-11, and at page 127, lines 1-20 and Table 7. Accordingly, claim 67 is fully supported by the application as filed and presents no new matter.

Entry of the amendments to the claims is therefore respectfully requested under 37 C.F.R. § 1.111.

II. The Objection to the Specification

The specification stands objected to because of an alleged inconsistency between Genbank Accession No. NM_005577.1 and the nucleic acid sequence provided as SEQ ID NO.:4. In particular, the PTO contends that Genbank Accession No. NM_005577.1 describes a nucleotide sequence only 6489 nucleotides in length, substantially shorter than SEQ ID NO.:4.

In response, Applicants respectfully invite the PTO's attention to Exhibit 1, providing the nucleotide sequence identified as Genbank Accession No. NM_005577.1. Applicants note that Genbank has updated this accession number with a second sequence, Genbank Accession No. NM_005577.2 and believe that the PTO may have inadvertently viewed the replacement sequence rather than the original. In any event, Applicants believe that Genbank Accession No. NM_005577.1 and SEQ ID NO.:4 define the same sequence and that there is no discrepancy. Accordingly, Applicants respectfully request that the objection to the specification be withdrawn.

III. The Objections to the Claims

Claim 50 stands objected to for reciting SEQ ID NO.: 95 twice. Claim 50 has been amended to correct this error. Thus, Applicants believe this objection is moot and respectfully request its withdrawal.

Claims 52 and 53 stand objected to as depending from a rejected independent claim, but otherwise allowable. Applicants believe these objections are moot in view of the amendments to the claims and request their withdrawal.

III. The Rejection of Claim 50 Under 35 U.S.C. § 112, Second Paragraph

Claim 50 stands rejected under 35 U.S.C. § 112, second paragraph, as indefinite as the claimed compound allegedly cannot comprise a sequence selected from a closed group of sequences. Without acquiescing to the propriety of the rejection, claim 50, as amended, no longer recites compounds that comprise a sequence selected from a closed group of sequences. As such, Applicants believe the rejection is moot and respectfully request its withdrawal.

IV. The Rejection of Claims 1, 3, and 17 Under 35 U.S.C. § 102(e)

Claims 1, 3, and 17 stand rejected as allegedly anticipated under 35 U.S.C. § 102(e) by Cai *et al.* (International Patent Publication No. WO 2004/108916). In particular, the PTO contends that Cai *et al.* teaches an antisense oligonucleotide of which nucleotides 2-26 are 96% complementary to nucleotides 12,805-12,829 of SEQ ID NO.:4 as recited by, for example, claim 1. Thus, according to the PTO, Cai *et al.* anticipates claims 1, 3, and 17.

In response, Applicants respectfully submit that Cai *et al.* cannot anticipate claim 1, and thus claims 3 and 17 depending therefrom, as currently amended. First, the oligonucleotide of Cai *et al.* is 26 nucleotides long, yet the PTO's calculation of percent complementarity between the oligonucleotide of Cai *et al.* and the present SEQ ID NO.:4 ignores the mismatch at position 1 of the oligonucleotide of Cai *et al.* Each nucleotide of the oligonucleotide of Cai *et al.* should be considered when calculating the percentage of complementarity. When each nucleotide of the oligonucleotide of Cai *et al.* is so considered, this oligonucleotide is calculated to be 92.3% complementary to SEQ ID NO.: 4.

Claim 1 recites an antisense compound that is at least 94% complementary to nucleotides 12380-13493 of SEQ ID NO.:4. As the oligonucleotide of Cai *et al.* is less than 94% identical to this sequence, it does not teach this element of claim 1. As such, Cai *et al.* cannot anticipate claim 1 as amended, or claims 3 and 17 depending therefrom, since it fails to teach each and every element of the invention as presently claimed. *See Merck & Co. v. Teva Pharmaceuticals USA, Inc.*, 68 USPQ2d 185 (Fed. Cir. 2003). Accordingly, Applicants assert that the rejection of claims 1, 3, and 17 as anticipated by Cai *et al.* is moot in view of the amendments to the claims and therefore request its withdrawal.

V. The Rejection of Claims 1, 3, and 17 Under 35 U.S.C. § 103(a)

Claims 1, 3, 6, 8-11, 17, 54-60, and 62-66 stand rejected under 35 U.S.C. § 103(a) as allegedly obvious over Ruoy *et al.* (International Patent Publication No. WO 99/65241) in view of Morishita *et al.* (*Circulation*, 1998, 98:1898-1904) and Baracchini *et al.* (U.S. Patent No. 5,801,154). Claims 1, 3, 6, 8-11, 17, and 54-66 further stand rejected in view of this combination of references in further view of Ramasamy *et al.* (U.S. Patent No. 6,525,191).

In particular, the PTO contends that Ruoy *et al.* teaches antisense nucleic acids targeted to apolipoprotein(a) and use of such antisense nucleic acids to downregulate gene expression. The PTO acknowledges that Ruoy does not teach antisense compounds that are at least 90% complementary to the coding region of apolipoprotein(a). However, the PTO contends that Morishita *et al.* teaches phosphorothioate modified ribozymes and a DNA oligonucleotide targeted to the coding region of kringle 4 of apolipoprotein(a). The PTO relies on Baracchini *et al.* and Ramasamy *et al.* to teach various chemical modifications of oligonucleotides (e.g., phosphorothioates, 2'-O-methoxyethyl sugar moieties, bicyclic nucleic acid sugar moieties, etc.). The PTO further contends that Baracchini states that the coding region of a gene is a preferred target for antisense modulation. Thus, according to the PTO, it would be obvious to one of ordinary skill in the art to make an antisense oligonucleotide to apolipoprotein(a) in view of the combination of Ruoy *et al.*, Morishita *et al.*, and Baracchini *et al.*

In response, Applicants respectfully submit that none of the references, either alone or in combination, provides a reason for one of ordinary skill in the art to select the particular region of the coding sequence of apolipoprotein(a) presently recited by independent claims 1 and 57. Further, Morishita *et al.*, as discussed below, specifically teaches away from antisense modulation of apolipoprotein(a), further demonstrating the non-obviousness of the claims.

A. The Legal Standard

The Supreme Court's decision in *Graham v. John Deere Co. of Kansas City*, 383 U.S.1 (1966) sets forth the controlling standard for assessing purported obviousness of a claimed invention: “[T]he scope and content of the prior art are … determined; differences between the prior art and the claims at issue are … ascertained; and the level of ordinary skill in the pertinent art resolved. Against this background the obviousness or nonobviousness of the subject matter is determined.” *See id.* at 17–18.

The Supreme Court's recent decision in *KSR. Int'l Co. v. Teleflex*, 127 S.Ct. 1727, (2007) provides guidance regarding exactly how the differences between the prior art and claimed invention are analyzed to assess the obviousness or non-obviousness of the claims. As the Supreme Court explained, “interrelated teachings of multiple patents; the effects of demands known to the design community or present in the marketplace; and the background knowledge possessed by a person having ordinary skill in the art” can all be assessed “to determine whether there was an apparent reason to combine the known elements” as recited by the claim at issue. *See id.* at 1731 (2007). The Supreme Court expressly cautioned that this reason should be explicitly stated. *See id.* Thus, the PTO must identify an explicit reason to combine the elements of the prior art in the manner defined by the claims at issue.

Moreover, the prior art must be considered in its entirety, including portions of the prior art that teach away from the claimed subject matter. *See W.L. Gore & Associates, Inc. v. Garlock Inc.*, 220 USPQ 303 (Fed. Cir. 1984). A reference may be said to teach away when a person of ordinary skill, upon reading the reference, … would be led in a direction divergent from that taken by the applicant.” *See Tec Air, Inc. v. Denso Mfg. Mich. Inc.*, 52 USPQ2d 1294, 1298, (Fed. Cir. 1999), quoted by *In re Haruna*, 58 USPQ2d 1517 (Fed. Cir. 2001).

Prior art references that teach away from the claimed combination should not be combined. *See In re Grasselli*, 218 USPQ 769 (Fed. Cir. 1983). Thus, if a prior art reference “did in fact teach away from [another prior art reference], then that finding alone can defeat

[an] obviousness" attack based on the combination of the two references. *See Winner International Royalty Corp. v. Wang*, 53 USPQ2d 1580 (Fed. Cir. 2000).

Further, "known disadvantages... that would naturally discourage search for new inventions may be taken into account in determining obviousness." *See United States v. Adams*, 383 U.S. 39, 52; 148 USPQ 479, 484 (1966). In fact, the inventor's achievement of the claimed invention by doing what others suggested should not be done is a fact strongly probative of nonobviousness. *See Kloser Speedsteel AB v. Crucible Inc.*, 230 USPQ 81 (Fed. Cir. 1986), *on rehearing* 231 USPQ 160 (Fed. Cir. 1986).

B. The Cited References Do Not Suggest an Antisense Compound at Least 90% or 94% Complementary to Nucleotides 12380-13493 of SEQ ID NO: 4

None of the cited references, either alone or in combination, teach or suggest an antisense compound at least 90% or 94% complementary to nucleotides 12380-13493 of SEQ ID NO: 4. Ruoy *et al.* neither teaches nor suggests that an antisense compound should be targeted to any particular region of the coding region of apolipoprotein(a). Further, as discussed extensively below, Morishita *et al.* teaches that antisense compounds, whether targeted to the coding region or otherwise, should not be used to modulate apolipoprotein(a) expression. As such, the combination of Ruoy *et al.* and Morishita *et al.* certainly fails to provide a reason why one of ordinary skill in the art should select the particular 1113 nucleotide region out of more than 13,000 nucleotides of SEQ ID NO.: 4 as a target for antisense modulation.

Moreover, neither Baracchini *et al.* nor Ramasamy *et al.* disclose anything regarding antisense modulation of apolipoprotein(a) expression. Rather, these references merely teach various chemical modifications of oligonucleotides and, in the case of Baracchini *et al.*, provides general teaching that antisense compounds can be targeted to the coding region of a gene. As such, neither of these references cure the deficiencies of Ruoy *et al.* and Morishita *et al.* discussed above. Accordingly, the combination of references, when considered as a whole, fails to teach or suggest each and every element of the invention as presently claimed. Further, the PTO has failed to identify a reason as required by the Supreme Court in *KSR v. Teleflex* "that would have prompted a person of ordinary skill in the relevant field to combine the elements in the way the claimed new invention does." *See KSR* at 1731. Therefore, Applicants respectfully submit that the PTO has failed to establish *prima facie* obviousness of the claimed invention.

C. Morishita *et al.* Teaches Away from the Claimed Invention

In addition, Morishita *et al.* specifically teaches away from antisense modulation of apolipoprotein(a) expression. At the paragraph bridging pages 1898 and 1899 of Morishita *et*

al., the authors consider whether to use antisense compounds or ribozymes to modulate apolipoprotein(a) expression. Morishita *et al.* concludes that ribozymes are superior to antisense compounds for modulating expression of this gene because, according to Morishita *et al.*, ribozymes are more effective for inhibiting target gene expression and because of the difficulty of using antisense compounds to selectively inhibit apolipoprotein(a) expression.

Indeed, Morishita *et al.* uses a DNA oligonucleotide without ribozyme activity as a negative control (see Morishita *et al.* at page 1899, under the heading “Synthesis of Ribozyme ON and Selection of Sequence Targets.” This DNA oligonucleotide did not in fact inhibit apolipoprotein(a) expression. See Morishita *et al.* at page 1901, Figure 2. Therefore, Morishita *et al.* teaches that ribozymes, rather than antisense compounds as recited by the present claims, should be used to modulate apolipoprotein(a) expression and thus teaches away from the invention as presently claimed.

Since Morishita *et al.* teaches away from antisense compounds targeted to apolipoprotein(a), it is improper to include Morishita *et al.* in an obviousness rejection of claims drawn to such antisense compounds. See *In re Grasselli* and *Winner International*. Further, the conclusion of Morishita *et al.* that antisense compounds targeted to apolipoprotein(a) should not be used to modulate apolipoprotein(a) expression is strongly probative of the nonobviousness of Applicants’ invention. See *Kloser Speedsteel*. Accordingly, Applicants respectfully submit that Morishita *et al.* actually provides evidence that the claimed antisense compounds are not obvious, contrary to the PTO’s assertion otherwise.

D. The Obviousness Rejections Should Be Withdrawn

Applicants respectfully submit that the references cited by the PTO, whether considered alone or in combination, fail to teach or suggest each and every element of the invention recited by the independent claims, claims 1 and 57, of the present application. As such, Applicants respectfully submit that claims 1 and 57, and each of the claims depending therefrom, are not obvious over the references cited by the PTO. Therefore, Applicants respectfully request that the rejection of claims 1, 3, 6, 8-11, 17, 54-60, and 62-66 under 35 U.S.C. § 103(a) as obvious over Ruoy *et al.* in view of Morishita *et al.* and Baracchini *et al.* and of claims 1, 3, 6, 8-11, 17, and 54-66 over this combination of references in further view of Ramasamy *et al.* be withdrawn.

VI. Double Patenting

Claims 1, 3, 6, 8-11, and 54-57 stand provisionally rejected under the doctrine of obviousness-type double patenting over claims 1, 2, and 4-11 of copending application no. 10/485,113. Without acquiescing to the propriety of the rejection, Applicants believe the

rejection is moot in view of the abandonment of copending application no. 10/485,113. Accordingly, Applicants respectfully request that the provisional rejection of claims 1, 3, 6, 8-11, and 54-57 for obviousness-type double patenting be withdrawn.

VII. Conclusion

In light of the above amendments and remarks, Applicants respectfully request that the PTO reconsider this application with a view towards allowance. The Examiner is invited to call the undersigned attorney at (650) 739-3949, if a telephone call could help resolve any remaining items.

Date: August 14, 2007


Respectfully submitted,
  56,056
David C. Pauling (Reg. No.)
For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

EXHIBIT 1
Genbank Accesion No. NM_005577.1

My NCBI [Sign In] [Register]

NCBI

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search for

Limits Preview/Index History Clipboard Details

Display Show Send to Hide: sequence all but gene, CDS and mRNA

Range: from to Reverse complemented strand Features: STS

1: NM_005577. Reports ...[gi:5031884] The record has been replaced by 116292749

Comment Features Sequence

LOCUS NM_005577 13938 bp mRNA linear PRI 19-SEP-2006
 DEFINITION Homo sapiens lipoprotein, Lp(a) (LPA), mRNA.
 ACCESSION NM_005577 XM_926329 XM_941794
 VERSION NM_005577.1 GI:5031884
 KEYWORDS .
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 13938)
 AUTHORS Becker, L., Nesheim, M.E. and Koschinsky, M.L.
 TITLE Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation
 JOURNAL Biochemistry 45 (32), 9919-9928 (2006)
 PUBMED 16893192
 REMARK GeneRIF: Cultured human hepatoma cells secrete an oxidase activity that dramatically enhances the rate of covalent Lp(a) assembly.
 REFERENCE 2 (bases 1 to 13938)
 AUTHORS Sotiriou, S.N., Orlova, V.V., Al-Fakhri, N., Ihanus, E., Economopoulou, M., Isermann, B., Bdeir, K., Nawroth, P.P., Preissner, K.T., Gahmberg, C.G., Koschinsky, M.L. and Chavakis, T.
 TITLE Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin
 JOURNAL FASEB J. 20 (3), 559-561 (2006)
 PUBMED 16403785
 REMARK GeneRIF: data demonstrate that Lp(a), via its apo(a) moiety, is a ligand for the beta2-integrin Mac-1, thereby facilitating inflammatory cell recruitment to atherosclerotic plaques; these observations suggest a novel mechanism for atherogenic properties of Lp(a)
 REFERENCE 3 (bases 1 to 13938)
 AUTHORS Unluhizarci, K., Muhtaroglu, S., Kabak, S., Bayram, F. and Kelestimur, F.
 TITLE Serum lipoprotein (a) levels in patients with diabetic foot lesions
 JOURNAL Diabetes Res. Clin. Pract. 71 (2), 119-123 (2006)
 PUBMED 16122830
 REMARK GeneRIF: Lp (a) levels may have a pathogenetic role in the development of gangrenous foot lesions in patients with diabetes mellitus.
 REFERENCE 4 (bases 1 to 13938)
 AUTHORS Edelstein, C., Yousef, M. and Scanu, A.M.
 TITLE Elements in the C terminus of apolipoprotein [a] responsible for

JOURNAL the binding to the tenth type III module of human fibronectin
 J. Lipid Res. 46 (12), 2673-2680 (2005)
 PUBMED 16150826
 REMARK GeneRIF: binding sites responsible for binding to fibronectin
 REFERENCE 5 (bases 1 to 13938)
 AUTHORS Devlin,C.M., Lee,S.J., Kuriakose,G., Spencer,C., Becker,L.,
 Grosskopf,I., Ko,C., Huang,L.S., Koschinsky,M.L., Cooper,A.D. and
 Tabas,I.
 TITLE An apolipoprotein(a) peptide delays chylomicron remnant clearance
 and increases plasma remnant lipoproteins and atherosclerosis in
 vivo
 JOURNAL Arterioscler. Thromb. Vasc. Biol. 25 (8), 1704-1710 (2005)
 PUBMED 15905467
 REMARK GeneRIF: high levels of apo(a)/Lp(a), perhaps acting via a specific
 cell-surface binding domain, inhibit hepatic clearance of remnants,
 leading to high plasma levels of remnant lipoproteins and markedly
 enhanced atherosclerosis
 REFERENCE 6 (bases 1 to 13938)
 AUTHORS Nardulli,M., Durlach,V., Pepe,G. and Angles-Cano,E.
 TITLE Mechanism for the homocysteine-enhanced antifibrinolytic potential
 of lipoprotein(a) in human plasma
 JOURNAL Thromb. Haemost. 94 (1), 75-81 (2005)
 PUBMED 16113787
 REMARK GeneRIF: lipoprotein(a) has a role in homocysteine-enhanced
 antifibrinolysis in human plasma
 REFERENCE 7 (bases 1 to 13938)
 AUTHORS Song,K.H., Ko,S.H., Kim,H.W., Ahn,Y.B., Lee,J.M., Son,H.S.,
 Yoon,K.H., Cha,B.Y., Lee,K.W. and Son,H.Y.
 TITLE Prospective study of lipoprotein(a) as a risk factor for
 deteriorating renal function in type 2 diabetic patients with overt
 proteinuria
 JOURNAL Diabetes Care 28 (7), 1718-1723 (2005)
 PUBMED 15983325
 REMARK GeneRIF: Lp(a) is an independent risk factor for the progression of
 diabetic nephropathy in type 2 diabetic patients with overt
 proteinuria.
 REFERENCE 8 (bases 1 to 13938)
 AUTHORS Schneider,M., Witztum,J.L., Young,S.G., Ludwig,E.H., Miller,E.R.,
 Tsimikas,S., Curtiss,L.K., Marcovina,S.M., Taylor,J.M., Lawn,R.M.,
 Innerarity,T.L. and Pitas,R.E.
 TITLE High-level lipoprotein [a] expression in transgenic mice: evidence
 for oxidized phospholipids in lipoprotein [a] but not in low
 density lipoproteins
 JOURNAL J. Lipid Res. 46 (4), 769-778 (2005)
 PUBMED 15654123
 REMARK GeneRIF: mechanism by which increased circulating levels of Lp[a]
 could contribute to atherogenesis
 REFERENCE 9 (bases 1 to 13938)
 AUTHORS Eliassen,K.A., Brodal,B.P., Svindland,A., Osmundsen,H., Ronning,H.,
 Djurovic,S. and Berg,K.
 TITLE Activity of peroxisomal enzymes, and levels of polyamines in
 LPA-transgenic mice on two different diets
 JOURNAL (er) Lipids Health Dis 4, 23 (2005)
 PUBMED 16202171
 REMARK GeneRIF: Suggest connection between peroxisomal enzyme activity &
 presence of human LPA gene in murine genome. Effect may be result
 of changes in oxidative processes in lipid metabolism rather than
 from direct effect of LPA gene on peroxisomal gene expression.
 REFERENCE 10 (bases 1 to 13938)
 AUTHORS Parson,W., Kraft,H.G., Niederstatter,H., Lingenhel,A.W., Kochl,S.,

TITLE Fresser, F. and Utermann, G.
 A common nonsense mutation in the repetitive Kringle IV-2 domain of
 human apolipoprotein(a) results in a truncated protein and low
 plasma Lp(a)
 JOURNAL Hum. Mutat. 24 (6), 474-480 (2004)
 PUBMED 15523644
 REFERENCE 11 (bases 1 to 13938)
 AUTHORS Lamanuzzi, L.B., Mtairag el, M., Pepe, G. and Angles-Cano, E.
 TITLE Neutrophils stimulated by apolipoprotein(a) generate fragments that
 are stronger inhibitors of plasmin formation than apo(a)
 JOURNAL Thromb. Haemost. 92 (5), 1066-1075 (2004)
 PUBMED 15543335
 REMARK GeneRIF: Stimulation of PMNs by apo(a) results in the formation of
 elastase-derived apo(a) fragments that produce a
 concentration-dependent decrease in the formation of plasmin
 12 (bases 1 to 13938)
 AUTHORS Diaz-Peromingo, J.A., Carbalal, D.G. and Alban-Salgado, A.
 TITLE Lipoprotein (a) in patients on hemodialysis
 JOURNAL Acta Med. Austriaca 31 (3), 73-75 (2004)
 PUBMED 15515480
 REMARK GeneRIF: Changes in Lp(a) levels were found and perhaps these
 changes may be related to the episodic inflammation affecting
 patients on hemodialysis.
 13 (bases 1 to 13938)
 AUTHORS Anderson, N.L., Polanski, M., Pieper, R., Gatlin, T., Tirumalai, R.S.,
 Conrads, T.P., Veenstra, T.D., Adkins, J.N., Pounds, J.G., Fagan, R. and
 Loble, A.
 TITLE The human plasma proteome: a nonredundant list developed by
 combination of four separate sources
 JOURNAL Mol. Cell Proteomics 3 (4), 311-326 (2004)
 PUBMED 14718574
 REFERENCE 14 (bases 1 to 13938)
 AUTHORS Frohlich, J., Dobiasova, M., Adler, L. and Francis, M.
 TITLE Gender differences in plasma levels of lipoprotein (a) in patients
 with angiographically proven coronary artery disease
 JOURNAL Physiol Res 53 (5), 481-486 (2004)
 PUBMED 15479125
 REMARK GeneRIF: Our findings suggest that Lp(a) is more strongly
 associated with aCAD+ in women than in men.
 15 (bases 1 to 13938)
 AUTHORS Bogavac-Stanojevic, N., Djurovic, S., Jelic-Ivanovic, Z.,
 Spasojevic-Kalimanovska, V. and Kalimanovska-Ostric, D.
 TITLE Circulating transforming growth factor-beta1, lipoprotein(a) and
 cellular adhesion molecules in angiographically assessed coronary
 artery disease
 JOURNAL Clin. Chem. Lab. Med. 41 (7), 893-898 (2003)
 PUBMED 12940514
 REMARK GeneRIF: Blood levels are higher in coronary artery disease
 patients compared with normal values.
 16 (bases 1 to 13938)
 AUTHORS Gazzaruso, C., Garzaniti, A., Falcone, C., Puija, A., Geroldi, D.,
 Giordanetti, S. and Fratino, P.
 TITLE Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after
 intracoronary stent placement in Type 2 diabetic patients
 JOURNAL J. Diabetes Complicat. 17 (3), 135-140 (2003)
 PUBMED 12738397
 REMARK GeneRIF: Lp(a) and apo(a) polymorphisms do not appear to be
 reliable markers of restenosis in patients with Type 2 diabetes
 mellitus.
 17 (bases 1 to 13938)

AUTHORS Nassir,F., Xie,Y. and Davidson,N.O.
 TITLE Apolipoprotein[a] secretion from hepatoma cells is regulated in a size-dependent manner by alterations in disulfide bond formation
 JOURNAL J. Lipid Res. 44 (4), 816-827 (2003)
 PUBMED 12562843
 REFERENCE 18 (bases 1 to 13938)
 AUTHORS Tian,H., Han,L., Ren,Y., Li,X. and Liang,J.
 TITLE Lipoprotein(a) level and lipids in type 2 diabetic patients and their normoglycemic first-degree relatives in type 2 diabetic pedigrees
 JOURNAL Diabetes Res. Clin. Pract. 59 (1), 63-69 (2003)
 PUBMED 12482643
 REMARK GeneRIF: Positive correlation of Lp(a) between type 2 diabetic patients and their offspring, suggesting a potential genetic control for Lp(a) levels in type 2 diabetics families.
 REFERENCE 19 (bases 1 to 13938)
 AUTHORS Barre,D.E.
 TITLE Apolipoprotein (a) mediates the lipoprotein (a)-induced biphasic shift in human platelet cyclic AMP
 JOURNAL Thromb. Res. 112 (5-6), 321-324 (2003)
 PUBMED 15041277
 REMARK GeneRIF: apo(a) mediates the Lp(a)-induced biphasic response in platelet c-AMP as the result of platelet exposure to increasing levels of Lp(a), up to a concentration of 25 mg/dl Lp(a)
 REFERENCE 20 (bases 1 to 13938)
 AUTHORS Kapetanopoulos,A., Fresser,F., Millonig,G., Shaul,Y., Baier,G. and Utermann,G.
 TITLE Direct interaction of the extracellular matrix protein DANCE with apolipoprotein(a) mediated by the kringle IV-type 2 domain
 JOURNAL Mol. Genet. Genomics 267 (4), 440-446 (2002)
 PUBMED 12111551
 REFERENCE 21 (bases 1 to 13938)
 AUTHORS Nawawi,H.M., Muhajir,M., Kian,Y.C., Mohamud,W.N., Yusoff,K. and Khalid,B.A.
 TITLE Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients
 JOURNAL Diabetes Res. Clin. Pract. 56 (3), 221-227 (2002)
 PUBMED 11947970
 REMARK GeneRIF: Type of diabetes and waist-hip ratio are important determinants of levels in diabetic patients [LIPOPROTEIN (A)]
 REFERENCE 22 (bases 1 to 13938)
 AUTHORS Cerrato,P., Imperiale,D., Fornengo,P., Bruno,G., Cassader,M., Maffeis,P., Cavallo Perin,P., Pagano,G. and Bergamasco,B.
 TITLE Higher lipoprotein (a) levels in atherothrombotic than lacunar ischemic cerebrovascular disease
 JOURNAL Neurology 58 (4), 653-655 (2002)
 PUBMED 11865151
 REMARK GeneRIF: Lipoprotein (a) promotes large vessel atheromatosis rather than small vessel arteriolosclerosis and favors thrombosis on atheromatous plaques by suppressing local fibrinolysis.
 REFERENCE 23 (bases 1 to 13938)
 AUTHORS Geethanjali,F.S., Jose,V.J. and Kanagasabapathy,A.S.
 TITLE Lipoprotein (a) phenotypes in south Indian patients with coronary artery disease
 JOURNAL Indian Heart J 54 (1), 50-53 (2002)
 PUBMED 11999088
 REMARK GeneRIF: Plasma lipoprotein (a) levels are significantly elevated in patients with coronary artery disease as compared to controls. The contribution of lipoprotein (a) phenotype to the lipoprotein (a) levels in our population, if any, is modest.

REFERENCE 24 (bases 1 to 13938)
 AUTHORS Cabrinety,N., Pisonero,M.J., Ajram,J., Armenteras,A. and Cuatrecasas,J.M.
 TITLE Lipoprotein (a) in obese children with a family history of cardiovascular disease
 JOURNAL J. Pediatr. Endocrinol. Metab. 15 (1), 77-80 (2002)
 PUBMED [11822583](#)
 REMARK GeneRIF: children's group with BMI > 30 and with family history of CVD presented higher levels in comparison to the less obese group with family history of CVD

REFERENCE 25 (bases 1 to 13938)
 AUTHORS Xue,S., Madison,E.L. and Miles,L.A.
 TITLE The Kringle V-protease domain is a fibrinogen binding region within Apo(a)
 JOURNAL Thromb. Haemost. 86 (5), 1229-1237 (2001)
 PUBMED [11816712](#)
 REMARK GeneRIF: The Apo(a) Kringle V-protease domain binds to plasmin-treated fibrinogen, competing with and sharing binding sites with Lp(a), and possibly participating in the Lp(a)-fibrinogen interaction.

REFERENCE 26 (bases 1 to 13938)
 AUTHORS Ogorelkova,M., Kraft,H.G., Ehnholm,C. and Utermann,G.
 TITLE Single nucleotide polymorphisms in exons of the apo(a) kringle IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians
 JOURNAL Hum. Mol. Genet. 10 (8), 815-824 (2001)
 PUBMED [11285247](#)

REFERENCE 27 (bases 1 to 13938)
 AUTHORS Klose,R., Fresser,F., Kochl,S., Parson,W., Kapetanopoulos,A., Fruchart-Najib,J., Baier,G. and Utermann,G.
 TITLE Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta - and gamma -chains
 JOURNAL J. Biol. Chem. 275 (49), 38206-38212 (2000)
 PUBMED [10980194](#)

REFERENCE 28 (bases 1 to 13938)
 AUTHORS Rosby,O. and Berg,K.
 TITLE LPA gene: interaction between the apolipoprotein(a) size ('kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level
 JOURNAL J. Intern. Med. 247 (1), 139-152 (2000)
 PUBMED [10672142](#)

REFERENCE 29 (bases 1 to 13938)
 AUTHORS Ogorelkova,M., Gruber,A. and Utermann,G.
 TITLE Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians
 JOURNAL Hum. Mol. Genet. 8 (11), 2087-2096 (1999)
 PUBMED [10484779](#)

REFERENCE 30 (bases 1 to 13938)
 AUTHORS Edelstein,C., Shapiro,S.D., Klezovitch,O. and Scanu,A.M.
 TITLE Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringle IV-4 and IV-5. Potential relevance to lipoprotein(a) biology
 JOURNAL J. Biol. Chem. 274 (15), 10019-10023 (1999)
 PUBMED [10187779](#)

REFERENCE 31 (bases 1 to 13938)
 AUTHORS Niemeier,A., Willnow,T., Dieplinger,H., Jacobsen,C., Meyer,N., Hilpert,J. and Beisiegel,U.
 TITLE Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro
 JOURNAL Arterioscler. Thromb. Vasc. Biol. 19 (3), 552-561 (1999)

PUBMED 10073957
REFERENCE 32 (bases 1 to 13938)
AUTHORS Bonen,D.K., Nassir,F., Hausman,A.M. and Davidson,N.O.
TITLE Inhibition of N-linked glycosylation results in retention of intracellular apo[a] in hepatoma cells, although nonglycosylated and immature forms of apolipoprotein[a] are competent to associate with apolipoprotein B-100 in vitro
JOURNAL J. Lipid Res. 39 (8), 1629-1640 (1998)
PUBMED 9717723
REFERENCE 33 (bases 1 to 13938)
AUTHORS Kochl,S., Fresser,F., Lobentanz,E., Baier,G. and Utermann,G.
TITLE Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain
JOURNAL Blood 90 (4), 1482-1489 (1997)
PUBMED 9269765
REFERENCE 34 (bases 1 to 13938)
AUTHORS Edelstein,C., Italia,J.A. and Scanu,A.M.
TITLE Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments
JOURNAL J. Biol. Chem. 272 (17), 11079-11087 (1997)
PUBMED 9111002
REFERENCE 35 (bases 1 to 13938)
AUTHORS Edelstein,C., Italia,J.A., Klezovitch,O. and Scanu,A.M.
TITLE Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a]
JOURNAL J. Lipid Res. 37 (8), 1786-1801 (1996)
PUBMED 3864963
REFERENCE 36 (bases 1 to 13938)
AUTHORS Grainger,D.J., Kemp,P.R., Liu,A.C., Lawn,R.M. and Metcalfe,J.C.
TITLE Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice
JOURNAL Nature 370 (6489), 460-462 (1994)
PUBMED 8047165
REFERENCE 37 (bases 1 to 13938)
AUTHORS Salonen,E.M., Jauhainen,M., Zardi,L., Vaheri,A. and Ehnholm,C.
TITLE Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it
JOURNAL EMBO J. 8 (13), 4035-4040 (1989)
PUBMED 2531657
REFERENCE 38 (bases 1 to 13938)
AUTHORS Frank,S.L., Klisak,I., Sparkes,R.S., Mohandas,T., Tomlinson,J.E., McLean,J.W., Lawn,R.M. and Lusis,A.J.
TITLE The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen
JOURNAL Hum. Genet. 79 (4), 352-356 (1988)
PUBMED 3410459
REFERENCE 39 (bases 1 to 13938)
AUTHORS McLean,J.W., Tomlinson,J.E., Kuang,W.J., Eaton,D.L., Chen,E.Y., Fless,G.M., Scanu,A.M. and Lawn,R.M.
TITLE cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
JOURNAL Nature 330 (6144), 132-137 (1987)
PUBMED 3670400
COMMENT PROVISIONAL REFSEQ: This record has not yet been subject to final NCBI review. The reference sequence was derived from X06290.1.
[WARNING] On Oct 20, 2006 this sequence was replaced by gi:116292749.
On or before Mar 4, 2006 this sequence version replaced

sig peptide

46..102

/gene="LPA"

mat peptide

103.13689

/gene="LPA"

STS

12579..12709

/gene="LPA"
 /standard_name="GDB:595276"
 /db_xref="UnisTS:158018"
STS 13694..13824
 /gene="LPA"
 /standard_name="STS-X06290"
 /db_xref="UnisTS:72928"
STS 13696..13938
 /gene="LPA"
 /standard_name="D6S1951"
 /db_xref="UnisTS:43503"
polyA site 13938
 /gene="LPA"
 /note="polyA site"
ORIGIN
1 ctgggattgg gacacacttt ctggacactg' ctggccagtc caaaaatgga acataaggaa
61 gtggttcttc tacttcttt atttctgaaa tcagcagcac ctgagcaaag ccatgtggtc
121 caggattgct accatggta tggacagagt tatcgaggca cgtactccac cactgtcaca
181 ggaaggacct gccaagctt gtcatctatg acaccacatc aacataatag gaccacagaa
241 aactacccaa atgctggctt gatcatgaac tactgcagga atccagatgc tgtggcagct
301 ccttattgtt atacgagggta tcccgggtc aggtgggagt actgcaacct gacgcaatgc
361 tcagacgcag aaggactgc cgtcgcgcct ccgactgtt ccggcgttcc aagcctagag
421 gctccttccg aacaagcacc gactgagcaa aggccctgggg tgcaggagtg ctaccatgg
481 aatggacaga gttatcgagg cacatactcc accactgtca caggaagaac ctgccaagct
541 tggtcatcta tgacaccaca ctgcatacg aatgcggcc aatactaccc aaatgctggc
601 ttgatcatga actactgcag gaatccagat gctgtggcag ctccttattt ttatcgagg
661 gatcccggtg tcaggtggga gtactgcaac ctgacgcatt gctcagacgc agaaggact
721 gccgtcgccg ctccgactgt taccgggtt ccaagcctag aggctccttc cgaacaagca
781 ccgactgagc aaaggcctgg ggtgcaggag tgctaccatg gtaatggaca gagttatcg
841 ggcacatact ccaccactgt cacaggaaga acctgccaag ctggcatac tatgacacca
901 cactcgccata gtcggacccc agaatactac ccaaattgtc gttgatcat gaactactgc
961 aggaatccag atgctgtggc agtccttata ttttatacgaa gggatccgg tgtcagggtgg
1021 gagtaactgca acctgacgc atgctcagac gcagaaggaa ctgcgcgcgc gcctccgact
1081 gttaccccg ttccaagcct agaggctcct tccgaacaag caccgactga gcaaaggcct
1141 ggggtgcagg agtgcatacca tggtaatggc cagagttatc gaggcacata ctccaccact
1201 gtcacaggaa gaacctgcca agcttggta tctatgacac cacactcgca tagtcggacc
1261 ccagaatact acccaaattgc tggctgatc atgaactact gcaggaatcc agatgtgt
1321 gcagctcctt attgttatac gaggatccc ggtgtcagg gggagtaactg caacctgacg
1381 caatgctcag acgcagaagg gactgcccgc ggcctccga ctgttacccc gttccaagc
1441 ctagaggctc cttccgaaca agcaccgact gagcaaaggc ctgggtgca ggagtgtac
1501 catggtaatg gacagagtt tcgaggcaca tactccacca ctgtcacagg aagaacctgc
1561 caagcttggg catctatgac accacactcg catagtcggc ccccagaata ctacccaaat
1621 gctggcttga tcatgaacta ctgcaggaaat ccagatgtc tggcagctcc ttattgttat
1681 acgagggtac ccgggtcag gtgggagtac tgcaacctga cgcatacg agacgcagaa
1741 gggactgccc tcgcgcctcc gactgttacc ccgggtccaa gcctagaggg tcctccgaa
1801 caagcaccga ctgagcaaaag gcctgggggt caggagtgtc accatggtaa tggacagagt
1861 tattcgaggca catactccac cactgtcaca ggaagaacct gccaagcttgc gtcatactatg
1921 acaccacact cgcatacg gaccccgaaa tactacccaa atgctggctt gatcatgaac
1981 tactgcagga atccagatgc tggcaggat ctttattgtt atacgaggaa tccgggtgtc
2041 aggtgggagt actgcaacct gacgcatacg tcagacgcag aaggactgc cgtcgccct
2101 ccgactgtt ccggcgttcc aacccctagag gtccttccg aacaaggcacc gactgagca
2161 aggcctgggg tgcaggagtg ctaccatgtt aatggacaga gttatcgagg cacatactcc
2221 accactgtca caggaagaac ctgccaagct tggcatcta tgacaccaca ctgcatacg
2281 ccgaccccgaaa aatactaccc aatgcgttgc ttgatcatga actactgcag gaatccagat
2341 gctgtggcag ctccattttt tttatcgagg gatccgggtc tggcaggaa gttatcgac
2401 ctgacgcata gtcagacgc agaaggact ggcgtcgcc ctccgactgt taccgggtt
2461 ccaaggcttag aggctccttc cgaacaagca ccgactgagc aaaggcctgg ggtgcaggag
2521 tgctaccatg gtaatggaca gagttatcgaa ggcacatacg ccaccactgt cacaggaaga
2581 acctgccaag ctggcatac tatgacacca cactcgccata gtcggacccc agaatactac
2641 ccaatgctg gttgatcat gaactactgc aggaatccag atgctgtggc agtccttata

2701 ttttatacga gggatcccg gtcaggtgg gactactgca acctgacgca atgctcagac
2761 gcagaaggga ctgcgtcgc gcctccgact gttaccccg ttccaaggct agaggctcct
2821 tccgaacaag caccgactga gcaaaaggct ggggtgcagg agtgcatacc tggtaatgga
2881 cagagttatc gaggcacata ctccaccact gtcacaggaa gaacctgcca agcttggta
2941 tctatgacac cacactcgca tagtcggacc ccagaataact acccaaatac tggcttgatc
3001 atgaactact gcaggaatcc agatgctgtg gcagtcctt attgttatac gaggatccc
3061 ggtgtcaggt gggagactg caacctgacg caatgctcag acgcagaagg gactgccgtc
3121 gcgcctccga ctgttaccc ggttccaagc ctagaggctc cttccgaaca agcaccgact
3181 gagcaaaggc ctgggggtca ggagtgtac catggtaatg gacagaggtt tcgaggcaca
3241 tactccacca ctgtcacagg aagaacctgc caagcttggt catctatgac accacactcg
3301 catagtcgga ccccagaata ctacccaaat gctggcttga tcatgaacta ctgcaggaat
3361 ccagatgtg tggcagctcc ttattgtt acgagggatc ccgggtgtcgt gttggaggtac
3421 tgcaacctga cgcaatgctc agacgcagaa gggactgccc tcgcgcctcc gactgttacc
3481 ccggttccaa gccttagaggc tccttccgaa caagcaccga ctgagcaaa gcttgggtg
3541 caggagtgtt accatggtaa tggacagagt tatcgaggca catactccac cactgtcaca
3601 ggaagaacct gccaagctt gtcatctatg acaccacact cgcatagtcg gaccccgaa
3661 tactacccaa atgctggctt gatcatgaac tactgcagga atccagatgc tttggcagct
3721 ctttattgtt atacgaggga tcccggtgtc aggtggaggt actgcaacact gacgcaatgc
3781 tcagacgcag aagggaactgc cgtcgcgcct ccgactgtt ccgggttcc aagcctagag
3841 gctccttccg aacaaggcacc gactgagcaa aggctgggg tgcaggagtg ctaccatggt
3901 aatggacaga gttatcgagg cacatactcc accactgtca caggaagaac ctgccaagct
3961 tggcatctt tgacaccaca ctcgcatacg cggaccccg aatactaccc aaatgctggc
4021 ttgatcatga actactgcag gaatccagat gctgtggcag ctccttattt ttatcgagg
4081 gatcccggtg tcaggtggga gtactgcaac ctgacgcaat gtcagacgc agaaggact
4141 gccgtcgcgc ctccgactgt taccgggtt ccaaggctcg aggctccctc cgaacaagca
4201 ccgactgagc aaaggcctgg ggtcaggag tgctaccatg gtaatggaca gagttatcga
4261 ggcacatact ccaccactgt cacaggaaga acctgccaag cttggtcatac tatgacacca
4321 cactcgatc gtcggacccc agaataactac ccaaatacgat gcttgcatac gaactactgc
4381 aggaatccag atgctgtggc agtccttata ttttatacga gggatcccg tgcagggtgg
4441 gagtaactgca acctgacgca atgctcagac gcagaaggga ctgcgtcgc gcctccact
4501 gttaccccg ttccaaggctt agaggcttcc tccgaacaag caccgactga gcaaaggct
4561 ggggtgcagg agtgcatacc tggtaatgga caggttatac gaggcacata ctccaccact
4621 gtcacaggaa gaaacctgcca agttggtca tctatgacac cacactcgca tagtcggacc
4681 ccagaataact acccaaatac tggctgtatc atgaactact gcaggaatcc agatgtgt
4741 gcagtcctt attgttatac gagggtccc ggtgtcaggt gggagactg caacactgacg
4801 caatgctcag acgcagaagg gactgcgcgtc gcgcctccga ctgttaccc gtttccaagc
4861 cttagggctc ctccgaaca agcaccgact gagcaaggc ctgggtgca ggagtgtac
4921 catggtaatg gacagagtt tcgaggcaca tactccacca ctgtcacagg aagaacactgc
4981 caagtttgtt catctatgac accacactcg catagtcgga ccccagaata ctacccaaat
5041 gctggcttga tcatgaacta ctgcaggaaat ccagatgtcg tggcagctcc ttattgtt
5101 acgagggttc ccgggtgtcgt gttggaggtac tgcaacctga cgcaatgtc agacgcagaa
5161 gggactgccc tcgcgcctcc gactgttacc ccgggttccaa gcctagaggc tcctccgaa
5221 caagcaccga ctgagcaaa gcttgggtg caggagtgtt accatggtaa tggacagagt
5281 ttcggaggca catactccac cactgtcaca ggaagaacct gccaagctg gtcatctatg
5341 acaccacact cgcatagtcg gaccccgaaa tactacccaa atgctgggtt gatcatgaac
5401 tactgcagga atccagatgc tttggcagct ctttattgtt atacgaggga tcccggtgtc
5461 aggtggaggt actgcaacact gacgcaatgc tcagacgcag aaggactgc cgtcgcgcct
5521 ccgactgtt ccgggttcc aacgcttagag gtcctccg aacaaggcacc gactgagca
5581 aggctgggg tgcaggagtg ctaccatgtt aatggacaga gttatcgagg cacatactcc
5641 accactgtca caggaagaac ctgccaagat tggtcatcta tgacaccaca ctgcatacg
5701 cggaccccg aatactaccc aaatgctggc ttgatcatga actactgcacg gaatccagat
5761 gctgtggcag ctccattttt ttatcgagg gatccgggtg tcagggtggaa gtactgcaac
5821 ctgacgcaat gtcagacgc agaaggact gccgtcgcgc ctccgactgt taccgggtt
5881 ccaaggcttag aggctccctc cgaacaaggca ccgactgcacg aaaggcctgg ggtgcaggag
5941 tgctaccatg gtaatggaca gagttatcgaa ggcacatactt ccaccactgt cacaggaaga
6001 acctgccaag ctgggtcatc tatgacacca cactcgata gtcggacccc agaataactac
6061 ccaaatgtcg gcttgcatac gaactactgc aggaatccag atgctgtggc agctccctt
6121 ttttatacga gggatcccg tttggcaggtgg gagtaactgca acctgacgca atgctcagac
6181 gcagaaggaa ctgcgtcgc gcctccgact gttaccccg ttccaaggctt agaggctt
6241 tccgaacaacg caccgactga gcaaaaggctt ggggtgcagg agtgcatacc tggtaatgga

6301 cagagttatc gaggcacata ctccaccact gtcacaggaa gaacctgcca agcttggtca
6361 tctatgacac cacactcgca tagtcggacc ccagaatact acccaaatgc tggcttgc
6421 atgaactact gcaggaatcc agatgctgtg gcagctcctt attgttatac gaggatccc
6481 ggtgtcaggt gggagtagctg caacctgacg caatgctcg acgcagaagg gactgccc
6541 gcgcctccga ctgttacccc gttccaagc ctagaggctc cttccgaaca agcaccgact
6601 gagcaaaggc ctgggtgca ggagtctac catggtaatg gacagaggtt tcgaggcaca
6661 tactccacca ctgtcacagg aagaacctgc caagcttggt catctatgac accacactcg
6721 catagtcgga ccccagaata ctacccaaat gctggcttga tcatgaacta ctgcaggaat
6781 ccagatgctg tggcagctcc ttattgtt acgagggatc ccgggtgtcag gtgggagtag
6841 tgcaacctga cgcaatgctc agacgcagaa gggactgccc tcgcgcctcc gactgttacc
6901 ccggttccaa gcctagaggc tccttccgaa caagcaccga ctgagcaaag gcctgggtg
6961 caggagtgt accatggtaa tggacagagt tatcgaggca catactccac cactgtcaca
7021 ggaagaacct gccaagctt gtcatctatg acaccacact cgcatagtcg gaccccgaaa
7081 tactacccaa atgctggctt gatcatgaac tactgcagga atccagatgc tggcagact
7141 ccttattgtt atacgaggga tcccgggtc aggtgggagt actgcaacct gacgcaatgc
7201 tcagacgcag aagggactgc cgtcgcgcct ccgactgtt aaccgggttcc aaggcttagag
7261 gctcctccg aacaagcacc gactgagcaa aggctgggg tgcaggagtg ctaccatgg
7321 aatggacaga gttatcgagg cacatactcc accactgtca caggaagaac ctgccaagct
7381 tggtcatcta tgacaccaca ctcgcatagt cggacccag aatactaccc aatgtctggc
7441 ttgatcatga actactgcag gaatccagat gctgtggcag ctccttattt ttatcatgagg
7501 gatcccggtg tcaggtggga gtactgcaac ctgacgcaat gctcagacgc agaaggact
7561 gccgtcgcgc ctccgactgt taccgggtt ccaaggcttag aggctccttc cgaacaagca
7621 ccgactgagc aaaggcctgg ggtcaggag tgctaccatg gtaatggaca gagttatcga
7681 ggcacatact ccaccactgt cacaggaaga acctgccaag cttggtcatac tatgacacca
7741 cactcgacata gtcggacccc agaataactac ccaaattgtc gcttgcatac gaactactgc
7801 aggaatccag atgctgtggc agtccttacg ttttatacga gggatcccg tggcaggtgg
7861 gagtaactgca acctgacgc acgttcacac gcagaaggga ctgcccgcgc gcctccgact
7921 gttaccccggttccaacgctt agaggctctt tccgaacaag caccgactga gcagaggcct
7981 ggggtgcagg agtgcatacc cggtaatggc cagagttatc gaggacata ctccaccact
8041 gtcactggaa gaaacctgcca agcttgcac tctatgacac cacactcgca tagtcggacc
8101 ccagaataact acccaaatgc tggcttgcatac atgaactact gcaggaatcc agatgttgc
8161 gcagctcctt attgttatac gaggatccc ggtgcaggt gggagtagtca accctgacgc
8221 caatgctcag acgcagaagg gacttcgcgc ggcctccga ctgttacccc gttccaaagc
8281 ctagaggctc cttccgaaca agcaccgact gagcaaaaggc ctgggtgc gggatgtac
8341 catggtaatg gacagagtt tcgaggcaca tactccacca ctgtcacagg aagaacactgc
8401 caagcttgcgt catctatgac accacactcg catagtcgaa ccccaaaaat ctacccaaat
8461 gctggcttga tcatgaacta ctgcaggaat ccagatgtc tggcagctcc ttattgtt
8521 acgagggatc ccgggtcag gtgggagtag tgcaacctga cgcatactgc agacgcagaa
8581 gggactgccc tcgcgcctcc gactgttacc ccgggtccaa gcctagaggc tcctccgaa
8641 caagcaccga ctgagcaaaag gcctgggtc caggagtgct accatggtaa tggacagact
8701 tattcgaggca catactccac cactgtcaca ggaagaacct gccaagctt gtcatactatg
8761 acaccacact cgcatactgc gaccccgaaa tactacccaa atgctggctt gatcatgaac
8821 tactgcagga atccagatgc tggcaggtc ctttattgtt atacgaggga tcccggtgc
8881 aggtgggagt actgcaacct gacgcaatgc tcagacgcag aaggactgc cgtcgcgc
8941 ccgactgttta ccccggttcc aaggcttagag gtccttccg aacaaggacc gactgaggc
9001 aggctgggg tgcaggagtg ctaccacggt aatggacaga gttatcgagg cacatactcc
9061 accactgtca ctggaaagac ctgccaagct tggcttgcatac tgacaccaca ctgcatact
9121 cggaccccaag aatactaccc aaatgctggc ttgatcatga actactgcag gaatccagat
9181 gctgtggcag ctccttattt ttatcatgagg gatccgggtc tggcaggtgg gttatcgac
9241 ctgacgcaat gtcagacgc agaaggact ggcgtcgcgc ctccgactgt taccgggtt
9301 ccaaggcttag aggctccttc cgaacaagca ccgactgagc agggcctgg ggtgcaggag
9361 tgctaccacg gtaatggaca gagttatcga ggcacatact ccaccactgt cactggaaa
9421 acctgccaag ctgggtcatac tatgacacca cactgcata gtcggacccc agaataactac
9481 ccaaattgtc gcttgcatac gaactactgc aggaatccag atgctgtggc agctcctt
9541 tggatccggg gggatccggg tggcaggtgg gaggactgtca acctgacgc acgttcagac
9601 gcagaaggga ctggcgtcgc gcctccgact gttacccggg tccaaagctt agaggctc
9661 tccgaacaag caccgactga gcagaggcc ggggtgcagg agtgcatacc cggtaatgg
9721 cagagttatc gaggcacata ctccaccact gtcactggaa gaaacctgcca agcttggtca
9781 tctatgacac cacactcgca tagtcggacc ccagaataact acccaaatgc tggcttgc
9841 atgaactact gcaggaatcc agatgttgc gcaacttcatttatac gaggatccc

9901 ggtgtcaggt gggagtactg caacctgacg caatgctag acgcagaagg gactgccgtc
9961 gcccctccga ctgttacccc ggttccaagc ctagaggctc cttccgaaca agcaccgact
10021 gacgagggc ctgggtgca ggagtgtac cacggtaatg gacagaggtt tcgaggcaca
10081 tactccacca ctgtcactgg aagaacctgc caagcttgg catctatgac accacactcg
10141 catagtcgga ccccagaata ctacccaaat gctggcttga tcatgaacta ctgcaggaat
10201 ccagatcctg tggcagcccc ttattgttat acgagggatc ccagtgtcgt gttggagtt
10261 tgcacacccaa cacaatgtc agacgcagaa gggactgccc tcgcgcctcc aactattacc
10321 ccgattccaa gcctagaggc tccttctgaa caagcaccaa ctgagcaaag gcctgggggt
10381 caggagtgtc accacggaaa tggacagagt tatcaaggca catacttcat tactgtcaca
10441 ggaagaacct gccaagctt gtcacatctat acaccacact cgcatagtcg gaccccgac
10501 tactacccaa atgctggctt gatcaagaac tactgcccga atccagatcc tgtggcagcc
10561 ccttgggttt atacaacaga tcccagtgtc aggtggaggt actgcaacct gacacgtgc
10621 tcagatgcag aatggactgc cttcgtccct ccgaatgttta ttctggctcc aagcttagag
10681 gcttttttgc aacaagcact gactgaggaa acccccgggg tacaggactg ctactaccat
10741 tatggacaga gttaccgggg cacatactcc accactgtca caggaagaac ttgccaagct
10801 tggtcatcta tgacaccaca ccagcatagt cggaccccgaaaactaccc aaatgctggc
10861 ctgaccagga actactgcag gaatccagat gctgagattc gcccttgggtt acaccat
10921 gatcccagtgc tcaggtggaa gtactgcaac ctgacacaat gcctgggtgac agaatcaagt
10981 gtccttgcaa ctctcacggt ggtcccgat ccaagcacag aggcttcttc tgaagaagca
11041 ccaacggagc aaagcccggtt ggtccaggat tgctaccatg gtgatggaca gagttatcga
11101 ggctcattctt ctaccactgt cacaggaagg acatgtcagt ttggccttc tatgacacca
11161 cactggcatc agaggacaac agaatattat ccaaattgggt gcctgaccag gaactactgc
11221 aggaatccag atgctgagat tagtccttgg tgttatacca tggatcccaa tgtoagatgg
11281 gagtaactgca acctgacacca atgtccagtg acagaatcaa gtgtccttgc gacgtccac
11341 gcttttctg aacaagcacc aacggagcaa agcccccacag tccaggactg ctaccatgg
11401 gatggacaga gttatcgagg ctcattctcc accactgttta caggaaggac atgtcagtct
11461 tggcctcttca tgacaccaca ctggcatcag agaaccacag aataactaccc aaatgggtgg
11521 ctgaccagga actactgcag gaatccagat gctgagattc gcccttgggtt ttataccat
11581 gatcccagtgc tcagatggaa gtactgcaac ctgacgcaat gtccagtgt ggaatcaact
11641 ctcctcacaa ctcacccggt ggtcccgat ccaagcacag agcttccttc tgaagaagca
11701 ccaactgaaa acagcaactgg ggtccaggac tgctaccatg gtgatggaca gagttatcga
11761 ggcacactctt ccaccactat cacaggaaga acatgtcagt ttggccttc tatgacacca
11821 cattggcatc ggaggatccc attatactat ccaaattgtcgt gcctgaccag gaactactgc
11881 aggaatccag atgctgagat tcgcccattgg tgttacacca tggatcccgat tgcagggtgg
11941 gagtaactgca acctgacacg atgtccagtg acagaatcga gtgtccttac aactccac
12001 gtggcccccgg ttccaagcac agaggcttcc tctgaacaag caccacccat gaaaagccct
12061 gtgttccagg attgttacca tggatggaa cggaggatc gaggcatatc ctccaccat
12121 gtcacaggaa ggacctgtca atcttggtca tctatgatac cacactggca tcagaggacc
12181 ccagaaaactt acccaatgc tggcctgacc gagaactact gcaggaatcc agattctgg
12241 aaacaaccctt ggttacac aaccgtatccg tggatgggtt gggaggactg caatctgaca
12301 caatgctcag aaacagaatc aggtgtccta gagactccca ctgttgttcc agttcaagc
12361 atggaggctc attctgaagc agcaccacact gagcaacccc ctgtggctcg gcagtgtc
12421 catggtaatg gccagatgttca tcgaggcaca ttctccacca ctgtcacagg aaggacatgt
12481 caatcttggt catccatgac accacaccgg catcagagga ccccgaaaaa ctacccaaat
12541 gatggcctga caatgaacta ctgcaggaaat ccagatgccc atacaggccc ttgggtttt
12601 accatggacc ccagcatcag gtggggatc tgcaacccat cgcgtatgc agacacagaa
12661 gggactgtgg tcgctccctt gactgtcatac caggttccaa gccttagggcc tccttctgaa
12721 caagactgtt tggggaaatggaa taccggggca agaaggcaac cactgttact
12781 gggacccat gccaggaatg ggctgcccgg gagcccccata gacacagcac gttcattcca
12841 gggacaaata aatggggcagg tctggaaaaa aattactgca gtaaccctga tggtgacatc
12901 aatggtccctt ggttacac aatgaatcca agaaaacttt ttgactactg tgatatccct
12961 ctctgtcattt ctcatttggg aagcctcaag tggagccggaa gaaatgtc
13021 ggaaggcattt taggggggtt tggggccac ccacatttccctt ggcctggca agtca
13081 agaacaaggt ttggaaagca cttctgttca ggcacccat tttccca gttgggtgt
13141 actgctgtc actgctgttca gaagtcctca aggccttcat cttacaaggtt catctgg
13201 gcacaccaag aagtgaacctt cgaatctcat gttcggaaa tagaagtgtc taggtgt
13261 ttggagccca cacaagcaga tattgttccat cttaaagctt gcaaggccctgc cgtcat
13321 gacaaagttaa tgccagttt tctggccatcc ccagactaca tggtcaccgc caggactgaa
13381 tggatcatca ctggctgggg agaaaacccaa ggtacccat gactggcct ttcacaggaa
13441 gcccagctcc ttgttatttttga gaatgaatgt tgcaatcaactt ataaatgttat ttgtgt
13441 gcccagctcc ttgttatttttga gaatgaatgt tgcaatcaactt ataaatgttat ttgtgt

13501 cattggcca gaggcaactga cagttgccag ggtgacagtg gagggcctct ggtttgc
13561 gagaaggaca aatacatttt acaaggagtc acttcttggg gtcttggctg tgcacgcccc
13621 aataagcctg gtgtctatgc tcgtgtttca aggtttgtta cttggattga gggaatgatg
13681 agaaataatt aattggacgg gagacagagt gaagcatcaa cctacttaga agctgaaacg
13741 tggtaagga ttttagcatgc tggaaataat agacagcaat caaacgaaga cactgttccc
13801 agtaccagc tatgccaaac cttggcattt ttggtatttt tgtgtataag ctttaaggt
13861 ctgactgaca aattctgtat taaggtgtca tagctatgac atttgttaaa aataaactct
13921 gcacttattt tgatttga

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 19 2007 13:56:00